Chiasma names new CEO
This article was originally published in Scrip
Chiasma, a US privately held biopharma company developing octreotide capsules for the orphan condition acromegaly, has appointed Mark Leuchtenberger president and CEO. Mr Leuchtenberger brings 25 years of industry experience to Chiasma, including CEO positions with Acusphere, Rib-X Pharmaceuticals, Targanta Therapeutics and Therion Biologics. From 1996 to 2002, he held multiple senior positions with Biogen, where he managed North American and international commercial operations. He currently serves as advisory board chair of the Massachusetts Emerging Technology Fund, MassDevelopment, and as a trustee and member of the Medical Education Committee, Beth Israel Deaconess Medical Center. And is also a board member of the Massachusetts Biotechnology Council.